A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha

Clin Adv Hematol Oncol. 2011 Jan;9(1):61-4.

Authors

Michael J Bradshaw¹, John C Cheville, Gary A Croghan

Affiliation

¹ Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA.

PMID: 21326149

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / physiopathology
Disease Progression
Humans
Indoles / administration & dosage
Indoles / therapeutic use*
Interferon-alpha / administration & dosage
Interferon-alpha / therapeutic use*
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / physiopathology
Male
Middle Aged
Neoplasm Metastasis
Pyrroles / administration & dosage
Pyrroles / therapeutic use*
Sunitinib
Ventricular Function, Left

Substances

Indoles
Interferon-alpha
Pyrroles
Sunitinib